View in EDS

Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).

Saved in:
Bibliographic Details
Title: Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
Authors: Post CCB; Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands; Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: c.c.b.post@lumc.nl., Westermann AM; Medical Oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands., Boere IA; Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands., Witteveen PO; Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands., Ottevanger PB; Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands., Sonke GS; Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Lalisang RI; Department of Internal Medicine, Division Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands., Putter H; Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands., Meershoek-Klein Kranenbarg E; Surgery, Leiden University Medical Center, Leiden, the Netherlands., Braak JPBM; Surgery, Leiden University Medical Center, Leiden, the Netherlands., Creutzberg CL; Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands., Bosse T; Pathology, Leiden University Medical Center, Leiden, the Netherlands., Kroep JR; Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
Source: Gynecologic oncology [Gynecol Oncol] 2022 May; Vol. 165 (2), pp. 223-229. Date of Electronic Publication: 2022 Mar 11.
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Academic Press Country of Publication: United States NLM ID: 0365304 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1095-6859 (Electronic) Linking ISSN: 00908258 NLM ISO Abbreviation: Gynecol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35287967
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Post+CCB%22">Post CCB</searchLink>; Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands; Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands. Electronic address: c.c.b.post@lumc.nl.<br /><searchLink fieldCode="AU" term="%22Westermann+AM%22">Westermann AM</searchLink>; Medical Oncology, Amsterdam University Medical Center, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Boere+IA%22">Boere IA</searchLink>; Medical Oncology, Erasmus Medical Center, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Witteveen+PO%22">Witteveen PO</searchLink>; Medical Oncology, University Medical Center Utrecht, Utrecht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Ottevanger+PB%22">Ottevanger PB</searchLink>; Medical Oncology, Radboud University Medical Center, Nijmegen, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Sonke+GS%22">Sonke GS</searchLink>; Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Lalisang+RI%22">Lalisang RI</searchLink>; Department of Internal Medicine, Division Medical Oncology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Putter+H%22">Putter H</searchLink>; Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Meershoek-Klein+Kranenbarg+E%22">Meershoek-Klein Kranenbarg E</searchLink>; Surgery, Leiden University Medical Center, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Braak+JPBM%22">Braak JPBM</searchLink>; Surgery, Leiden University Medical Center, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Creutzberg+CL%22">Creutzberg CL</searchLink>; Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Bosse+T%22">Bosse T</searchLink>; Pathology, Leiden University Medical Center, Leiden, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Kroep+JR%22">Kroep JR</searchLink>; Medical Oncology, Leiden University Medical Center, Leiden, the Netherlands.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%220365304%22">Gynecologic oncology</searchLink> [Gynecol Oncol] 2022 May; Vol. 165 (2), pp. 223-229. <i>Date of Electronic Publication: </i>2022 Mar 11.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Academic+Press%22">Academic Press </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>0365304 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1095-6859 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200908258%22">00908258 </searchLink><i>NLM ISO Abbreviation: </i>Gynecol Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35287967
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.ygyno.2022.02.025
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 223
    Titles:
      – TitleFull: Efficacy and safety of durvalumab with olaparib in metastatic or recurrent endometrial cancer (phase II DOMEC trial).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Post CCB
      – PersonEntity:
          Name:
            NameFull: Westermann AM
      – PersonEntity:
          Name:
            NameFull: Boere IA
      – PersonEntity:
          Name:
            NameFull: Witteveen PO
      – PersonEntity:
          Name:
            NameFull: Ottevanger PB
      – PersonEntity:
          Name:
            NameFull: Sonke GS
      – PersonEntity:
          Name:
            NameFull: Lalisang RI
      – PersonEntity:
          Name:
            NameFull: Putter H
      – PersonEntity:
          Name:
            NameFull: Meershoek-Klein Kranenbarg E
      – PersonEntity:
          Name:
            NameFull: Braak JPBM
      – PersonEntity:
          Name:
            NameFull: Creutzberg CL
      – PersonEntity:
          Name:
            NameFull: Bosse T
      – PersonEntity:
          Name:
            NameFull: Kroep JR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 05
              Text: 2022 May
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-electronic
              Value: 1095-6859
          Numbering:
            – Type: volume
              Value: 165
            – Type: issue
              Value: 2
          Titles:
            – TitleFull: Gynecologic oncology
              Type: main
ResultId 1